Celcuity Inc.

Contributing Author

Recent Articles by Celcuity Inc.

May-14	Celcuity Inc. Reports Release of First Quarter 2026 Financial Results and Provides Corporate Update CELC +8.23% GlobeNewswire
May-14	Celcuity's Phase 3 VIKTORIA-2 Trial of Gedatolisib as a First-Line Treatment for HR+/HER2- Advanced Breast Cancer Expanding to Include Endocrine-Sensitive Patients CELC +8.23% GlobeNewswire
May-07	Celcuity Schedules Release of First Quarter 2026 Financial Results and Webcast/Conference Call CELC -6.26% GlobeNewswire
May-01	Celcuity's Phase 3 VIKTORIA-1 Trial Achieves Primary Endpoint With Clinically Meaningful Improvement in Progression-Free Survival in PIK3CA Mutant Cohort CELC +15.38% CELC GlobeNewswire
Mar-25	Celcuity Inc. Reports Release of Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update CELC +8.05% GlobeNewswire
Mar-18	Celcuity Schedules Release of Fourth Quarter and Full Year 2025 Financial Results and Webcast/Conference Call CELC GlobeNewswire
Mar-09	Celcuity Announces Publication of Results from PIK3CA Wild-Type Cohort of Phase 3 VIKTORIA-1 Study of Gedatolisib Regimens in HR+/HER2- Advanced Breast Cancer in Journal of Clinical Oncology CELC GlobeNewswire
Feb-25	Celcuity To Participate in Upcoming Investor Conferences CELC GlobeNewswire
Feb-12	Celcuity Appoints Charles Romp to its Board of Directors CELC GlobeNewswire
Feb-04	Celcuity to Present at Upcoming Guggenheim Emerging Outlook: Biotech Summit 2026 CELC GlobeNewswire
Jan-20	Celcuity Announces FDA Acceptance of New Drug Application for Gedatolisib in HR+/HER2-/PIK3CA Wild-Type Advanced Breast Cancer CELC GlobeNewswire
Dec-11	Celcuity Presents Updated Results from the PIK3CA Wild-Type Cohort of the Phase 3 VIKTORIA-1 Trial at the 2025 San Antonio Breast Cancer Symposium CELC GlobeNewswire
Nov-26	Celcuity to Present Updated Data from the PIK3CA Wild-Type Cohort of the Phase 3 VIKTORIA-1 Trial at the 2025 San Antonio Breast Cancer Symposium CELC GlobeNewswire
Nov-26	Celcuity To Present at Upcoming 8th Annual Evercore Healthcare Conference CELC GlobeNewswire
Nov-17	Celcuity Announces Completion of Submission of Its New Drug Application to the U.S. FDA for Gedatolisib in HR+/HER2-/PIK3CA Wild-Type Advanced Breast Cancer CELC GlobeNewswire
Nov-12	Celcuity Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update CELC +7.56% GlobeNewswire
Nov-05	Celcuity Inc. Schedules Release of Third Quarter 2025 Financial Results and Webcast/Conference Call CELC GlobeNewswire
Nov-04	Celcuity To Present at Upcoming Stifel 2025 Healthcare Conference CELC GlobeNewswire
Oct-18	Celcuity Provides Update on Status of the PIK3CA Mutated Cohort of Phase 3 VIKTORIA-1 Trial and Releases Additional Data Analysis From Phase 1b Clinical Trial CELC GlobeNewswire
Oct-18	Detailed Results from PIK3CA Wild-Type Cohort of Phase 3 VIKTORIA-1 Trial Presented at 2025 ESMO Congress Demonstrate Potential for Gedatolisib Regimens to be Practice Changing for Patients with HR+/HER2- Advanced Breast Cancer CELC GlobeNewswire
Oct-18	Celcuity Presents Updated Data at the 2025 ESMO Congress from Phase 1 Study Evaluating Gedatolisib Plus Darolutamide in Men with Metastatic Castration Resistant Prostate Cancer ("mCRPC") CELC GlobeNewswire
Sep-22	Celcuity to Present Results from the Pivotal Phase 3 VIKTORIA-1 Trial at the 2025 European Society for Medical Oncology (ESMO) Congress CELC GlobeNewswire
Sep-09	Celcuity Announces Upsized Senior Secured Term Loan Facility of $500 Million with Innovatus Capital Partners and Oxford Finance CELC -7.96% CELC GlobeNewswire
Aug-27	Celcuity to Initiate NDA Submission of Gedatolisib in PIK3CA Wild-Type Cohort in HR+/HER2- Advanced Breast Cancer Under FDA's Real-Time Oncology Review Program CELC +9.29% CELC GlobeNewswire
Aug-14	Celcuity Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate Update CELC GlobeNewswire
Aug-07	Celcuity Inc. Schedules Release of Second Quarter 2025 Financial Results and Webcast/Conference Call CELC GlobeNewswire
Jul-30	Celcuity Inc. Announces Pricing of Concurrent Public Offerings of 2.750% Convertible Senior Notes Due 2031 and Common Stock and Pre-Funded Warrants CELC GlobeNewswire
Jul-28	Celcuity Inc. Announces Concurrent Public Offerings of Convertible Senior Notes Due 2031 and Common Stock CELC +167.18% GlobeNewswire
Jul-28	Celcuity Announces Clinically Meaningful Improvement in Both Progression-Free Survival ("PFS") Primary Endpoints from PIK3CA Wild-Type Cohort of Phase 3 VIKTORIA-1 Trial CELC +167.18% GlobeNewswire
Jul-25	Celcuity to Announce Topline Results for the PIK3CA Wild-Type Cohort from Phase 3 VIKTORIA-1 Trial in HR+/HER2- Advanced Breast Cancer CELC GlobeNewswire
Jul-24	Celcuity Announces First Patient Dosed in Phase 3 VIKTORIA-2 Clinical Trial of Gedatolisib as a First-Line Treatment for HR+/HER2- Advanced Breast Cancer CELC GlobeNewswire
Jul-14	Celcuity Announces Issuance of New Patent for Gedatolisib that Extends Patent Exclusivity into 2042 CELC GlobeNewswire
Jun-30	Celcuity Reports Clinical Data from Two Early Phase Studies of Gedatolisib CELC +6.46% GlobeNewswire
May-21	Celcuity To Present at Upcoming TD Cowen and Jefferies Investor Conferences CELC GlobeNewswire
May-14	Celcuity Inc. Reports First Quarter 2025 Financial Results and Provides Corporate Update CELC GlobeNewswire
May-07	Celcuity Inc. Schedules Release of First Quarter 2025 Financial Results and Webcast/Conference Call CELC GlobeNewswire

Celcuity Inc.

Recent Articles by Celcuity Inc.

Upgrade your Finviz experience